Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366106 · ClinicalTrials.gov registry record · Phase 2
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00366106 is a Phase 2 study that was terminated before completion, run by Accelerated Community Oncology Research Network. The registered enrollment target is 32 participants.
The verdict
NCT00366106, a Phase 2 study, was terminated before completion, sponsored by Accelerated Community Oncology Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
Interventions
- DRUG dexamethasone
- DRUG bortezomib
- DRUG doxorubicin HCl liposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366106
The ClinicalTrials.gov registry entry for NCT00366106 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00366106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366106 about?
NCT00366106 is a clinical study titled "Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma". The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
What is the current status of trial NCT00366106?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00366106?
The interventions under investigation include: dexamethasone (DRUG), bortezomib (DRUG), doxorubicin HCl liposome (DRUG).
Who is sponsoring clinical trial NCT00366106?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.